戻る Agenda
Communicating Clinical Trial Results: Targeting the Patient Audience
Session Chair(s)
David B. Clemow, PhD
Advisor, Scientific Communications Information Strategy
Eli Lilly and Company, United States
This session will describe current venues where drug development organizations communicate clinical trial results to patients, how to best communicate, and the importance of meeting patients' needs for them and the drug development organization.
This session has been developed by the DIA Medical Writing, Patient Engagement, Medical Communications, and Clinical Trial Disclosure Communities.
Learning Objective : Describe current venues/channels where drug development organizations communicate clinical trial results to the patient; Illustrate how to best compose medical communications to meet patient needs; Discuss appropriate writing levels, important content components, and key considerations; Summarize the importance of meeting patient audience needs for them and the drug development organization.
Speaker(s)
Communicating Medical Information
David P. Leventhal, MBA
Pfizer Inc, United States
Enterprise Clinical Trial Data Sharing Lead, Global Data Dissemination
Patient Perspective on Communication
Colleen Zak, BSN
ARPKD/CHF Alliance, United States
Founder / President
Communicating Through Clinical Trial Disclosures
Barbara Godlew, RN
Eli Lilly and Company, United States
Associate Consultant, Scientific Communications, GSC-Bio-Medicines
Communicating Through Advertising/Promotion
David B. Clemow, PhD
Eli Lilly and Company, United States
Advisor, Scientific Communications Information Strategy